Your Part D Drug Plan Costs $0, Medicare Still Bills You Up to $91
A zero-premium Part D plan can still trigger the IRMAA surcharge, adding as much as $91 a month for certain retirees....
Understanding what not to do when investing in crypto can save you from significant losses. Equip yourself with the right knowledge.
26,979 articlesA zero-premium Part D plan can still trigger the IRMAA surcharge, adding as much as $91 a month for certain retirees....
Pfizer faces a trio of headwinds: a CFO departure, a clinical miss, and a billion-dollar bet on Seagen. This article ...
Two global asset managers, two different paths to growth. This analysis pits BlackRock and Invesco against each other...
When a top executive sells shares, investors tune in. This article breaks down what a recent move by Ladder Capital's...
AMD has surged in 2026 and is flirting with a $1 trillion market cap. This deep dive examines the drivers, risks, and...
Micron looks cheaper than its earnings prospects suggest, but a closer look reveals cyclicality, demand swings, and r...
A high-profile insider sale at PTC Therapeutics coincides with a milestone for product revenue. This article breaks d...
Netflix has chased big bets beyond subscribers, but the road from ambition to profits is rocky. This article breaks d...
Aflac has a remarkable 43-year streak of raising its dividend, a hallmark many income investors look for. But that st...
Ark Invest’s latest stance on quantum computing raises questions for Rigetti Computing. This guide breaks down the im...
In a world obsessed with weight-loss drugs, a different growth engine quietly powers ahead. This article explains why...
Markets shift as political headlines evolve in the days after biggest defeat. This analysis explains how households m...